-
Analyst Opinions
NewUnited Kingdom (UK) Bancassurance Distribution Dynamics and Future Market, 2023 Update
This report discusses the bancassurance landscape for UK personal and commercial insurance. This includes discussion of the SME market, with due consideration given to smaller businesses and their comparatively simpler insurance needs. In addition, market leaders are outlined and consumer purchasing and switching behaviors are discussed. The bancassurance distribution landscape in the UK varies between personal and commercial lines. Banks account for 6.2% of business within personal lines and 19.9% within commercial lines, respectively. Bancassurance plays a crucial role as...
-
Thematic Analysis
NewStrategic Partnerships in Fintech – Thematic Intelligence
Strategic Partnerships in Fintech Thematic Report Overview Strategic partnerships for fintech companies can include traditional vendor relationships, new niche fintech partners, big tech partners, and/or bank-as-a-service of distribution arrangements with firms outside of financial services. The right partnership can deliver overnight scale via access to new markets or customers or neutralize a disintermediating threat.Moreover, working with proven partners and business models for distribution or as a tech partner will be more attractive. The ‘strategic partnerships in fintech’ thematic intelligence report...
-
Thematic Analysis
NewSocial Media in Banking – Thematic Intelligence
Social Media in Banking Thematic Report Overview Social media companies will increasingly diversify away from their ad-funded business model in the face of increased regulatory scrutiny. Social media in banking thematic report maps out the prospects of social media giants for a deep assault on financial services, and how incumbent banks might respond. The report shares findings from GlobalData’s 2023 Financial Services Consumer Survey, which covers consumer openness to a wide variety of different types of financial services from different...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBS-2418 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RBS-2418 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RBS-2418 in Colorectal Cancer Drug Details: RBS-2418 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBS-2418 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RBS-2418 in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RBS-2418 in Hepatocellular Carcinoma Drug Details: RBS-2418 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBS-2418 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RBS-2418 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RBS-2418 in Pancreatic Cancer Drug Details: RBS-2418 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBS-2418 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RBS-2418 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RBS-2418 in Solid Tumor Drug Details: RBS-2418 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Camrelizumab (Airuika)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Pucotenlimab (Puyouheng)...
-
Product Insights
United Kingdom (UK) SME Insurance Market Size, Trends, Competitor Dynamics and Opportunities
United Kingdom (UK) SME Insurance Market Report Overview Despite the significant economic challenges faced by small and medium-sized enterprises (SMEs) in recent years, the number of SMEs still increased in the UK in 2023. This growth highlights the importance of these companies as a source of business growth in the commercial insurance sector. Since SME switching behavior has increased, insurers should offer cheaper or more affordable policies. The UK SME insurance market research report presents information on the leading insurers...